1st Circ. Says Apellis Disclosures Weren't 'Half-Truths'
A First Circuit panel on Wednesday affirmed the dismissal of a securities fraud lawsuit accusing Apellis Pharmaceuticals and some of its top executives of misleading investors about the safety testing of...To view the full article, register now.
Already a subscriber? Click here to view full article